secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001213900-24-037205
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx prelim Q1 revenue $18.5-19.2M (+40% YoY); ahead of consensus
-----------------------------------------------------------------------

- Revenue expected between $18.5M and $19.2M for Q1 2024, over 40% growth YoY; GAAP net loss $(8.2)-$(7.0)M.
- Adjusted EBITDA loss of $(1.0)-$(0.7)M; results driven by DAAP platform and October 2023 Medicx acquisition.
- Signed 9 new Dynamic Audience Activation Platform (DAAP) deals in Q1; cross-selling ahead of internal expectations.
- Medicx integration ahead of schedule; management estimates $2.8B potential opportunity from existing brands alone.
- Earnings call scheduled for May 14, 2024 at 4:30 p.m. ET to discuss full Q1 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024037205/0001213900-24-037205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024037205/ea0204901-8k_optimizer.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-037205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer